TAM
APLS

Tiverton Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Tiverton Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$111K Buy
+4,628
New +$127K ﹤0.01% 637
2019
Q1 		– Sell
-8,238
Closed -$108K – 653
2018
Q4 		$108K Buy
+8,238
New +$126K 0.01% 359

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Tiverton Asset Management's APLS Position: Q3 2019 in Review

Tiverton Asset Management opened a new position in Apellis Pharmaceuticals (APLS) in Q3 2019: 4,628 shares worth $111K. The stake represents ﹤0.01% of the portfolio and ranks #637 among its holdings. This is a return to the name: Tiverton Asset Management previously reported a position in APLS as recently as Q4 2018.

Tiverton Asset Management first reported a position in APLS in Q4 2018 and has held it in 2 quarters since. 129 funds tracked by Wall St. Rank hold APLS as of Q3 2019.

  • Tiverton Asset Management held 4,628 shares of Apellis Pharmaceuticals worth $111K as of Q3 2019.
  • Apellis Pharmaceuticals was a new Tiverton Asset Management position in Q3 2019.
  • Apellis Pharmaceuticals made up ﹤0.01% of Tiverton Asset Management's portfolio in Q3 2019, its #637 holding.
  • Tiverton Asset Management first reported a position in Apellis Pharmaceuticals in Q4 2018 and has held it in 2 quarters since.
  • 129 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.